anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to enzymes from the specific groups of calpain proteases, which take part in a plurality of metabolic processes, e.g. by acting on the apoptosis, for certain cancerous diseases and during cell migration. The invention also relates to enzymes from the group of metalloproteases which develop, e.g. activities during fertilisation, and take part in blood pressure regulation as ACEs and as collagenases in collagen metabolism. A potential need of such enzymes is mainly covered today by plant and animal sources. Known organisms in which such proteases naturally occur exclusively come from warmer regions, such that a costly heat supply necessitating complex apparatus is required during the production thereof. Organisms comprising enzymes adapted to the cold are known however. The invention thus also relates to nucleic acid sequences coding for a calpain 7 protease and a zinc metalloprotease, which originate from the marine diatoms Fragilariopsis cylindrus adapted to the cold and correspond to SEQ ID No.1, SEQ ID No.2 or functional variants or fragments having at least 8 nucleotides thereof.
Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase human increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan. In the doses administered, hyaluronidase human in RITUXAN HYCELA acts locally.

The effects of hyaluronidase human are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

Hyaluronidase human has been shown to increase the absorption rate of a rituximab product into the systemic circulation when given in the subcutis of Göttingen Minipigs.
PURPOSE:To provide a skin-coating agent having high adhesivity to the skin and cleanable and removable easily compared with conventional collodion, and useful as a skin-protecting agent and a drug for the transcutaneous administration, by dissolving cellulose acetate phthalate as a film-forming agent in a solvent. CONSTITUTION:Cellulose acetate phthalate or hydroxypropylmethylcellulose phthalate is dissolved in a solvent (e.g. ethanol, propyl alcohol, ether, etc.) at a ratio of 3-30wt%, and the obtained solution is used as the objective skin-coating agent. Preferably, a plasticizer (e.g. polyglycol, PEG, higher hydrocarbon, etc.) is added to the agent in an amount of 5-30% based on the film-forming agent. The agent forms a coating film adhering closely to the skin, and protects the skin. When the agent contains a drug for transcutaneous administration, the drug is released slowly from the protecting film, and exhibits systemic drug action. It has remarkable effect for the remedy of corn.
Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (\>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
The invention discloses an antigen polypeptide, a polypeptide composition and a vaccine for preparing a bovine foot and mouth disease A-type polypeptide vaccine. The polypeptide composition comprises a polypeptide obtained by connecting the polypeptide fragment shown in sequence 1 with the polypeptide fragment shown in sequence 5. The vaccine provided by the invention comprises the polypeptide composition. The bovine foot and mouth disease A type polypeptide vaccine provided by the invention has good immune potency, so that the problems of fever, red and swollen caused by the traditional vaccine cannot be triggered. The vaccine provided by the invention can effectively response the antigenic variation of the current foot and mouth disease virus, is free of biological safety, easy for large-scale synthesize and has a good application future. The invention additionally discloses a preparation method of the polypeptide and the polypeptide vaccine and a pharmaceutical application thereof.
Group 1 will be administered 266 mg of Exparel, diluted to 30 mL. Group 2 will be given 28 mL of 0.375% bupivacaine and 8mg/2 mL dexamethasone.Before injection of the study medication, 2mL of normal saline with be injected under ultrasound visualization to ensure needle tip is in the transversus abdominis plane.Randomization will occur following the written informed consent and prior to the start of the surgical procedure. Postoperatively, study patients will receive intravenous acetaminophen 1000mg every 8 hours for 3 doses, then oral acetaminophen 650mg every 6 hours. Subjects will also have patient-controlled analgesia (PCA) with morphine or hydromorphone. The research staff recording data will be blinded to the treatment group. Demographic data will be recorded, including age, date of birth, height and weight to ensure similarity between the two groups. A medical history will be obtained as well as surgical and anesthesia details. Study patients will be followed for 72 hours postoperatively to record the amount of opioid consumption, as well as other pain score data using the Visual Analogue Scale (VAS).The subject's participation will end 72 hours after surgery. A telephone interview will occur with the subject if hospital discharge occurs prior to 72 hours.
The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
PURPOSE:A stable foaming vaginal suppository for contraception, comprising anhydrous sodium sulfate, anhydrous silica gel, etc. as a stabilizer, polyethylene glycol as a base, and a combination of an acidic substance and a basic substance as a foaming agent. CONSTITUTION:A foaming vaginal suppository containing 0.1-20wt% stabilizer properly selected from anhydrous sodium sulfate, anhydrous silica gel, dried magnesium silicate, dried aluminum silicate, dired calcium carboxymethylcellulose, dried microcrystalline cellulose, dried starch, and dried calcium phosphate.  The vaginal suppository comprises polyethylene glycol as a base and a combination of an acidic substance such as phosphoric acid, citric acid, etc. and a basic substance such as NaHCO3, etc. as a foaming agent. The addition of the stabilizer prevents reduction in foam amount caused by the progress of a neutralization reaction with time during administration and expansion of a packed article caused by evolved gas.
Methods, systems, and machine-readable mediums for providing clinical appropriateness information. One system includes a server and a plurality of clinical decision support (“CDS”) systems. Each CDS system includes a portal accessible over a communication network. The server includes an electronic processor. The electronic processor is configured to receive input, identify a set of CDS systems, and for each CDS system included in the set of CDS systems, establish electronic communication with the portal included in the CDS system, submit a request for appropriateness information to the CDS system based on the input through the portal, and receive appropriateness information from the CDS system. The electronic processor is also configured to aggregate the appropriateness information received from each CDS system included in the set of CDS systems to generate an aggregated list and display the aggregated list on a display device.
PURPOSE:A makeup cosmetic, obtained by blending flaky processed powder prepared by coating the surface of flaky inorganic powder having the major axis, minor axis and thickness within specific ranges with titanium oxide and/or iron oxide and having smooth extensibility as well as improved adhesive and hiding properties. CONSTITUTION:A cosmetic obtained by coating the surface of flaky inorganic power, particularly cleaved inorganic powder, e.g. cleaved talc. cleaved mica, etc.,having 0.5-50mu major axis, 0.2-30mu minor axis and 0.005-0.1mu thickness, more preferably both the major and the minor axes within the range of 0.5-20mu and the thickness within the range of 0.01-0.1mu with titanium oxide and/or iron oxide, preferably at 1-80wt% covering ratio based on the total flaky processed powder. The amount of the blended flaky processed power is preferably 0.5-85wt% based on the total cosmetic. EFFECT:Thin makeup finish.
PROBLEM TO BE SOLVED: To obtain composite particles which show excellent spreading property, orienting property, shielding property, etc., when the particles are compounded in a cosmetic material or the like, which show properly controlled aggregating property of metal (compd.) fine particles and catalytic reactivity, and which are excellent in such a use as to shield from UV rays, by surrounding metal (compd.) fine particles with silica having a specified or smaller percentage of a crystalline isolated silicate amt. to make a composite material. SOLUTION: The silica used has <10% crystalline isolated silica measured by X-ray diffraction analysis. The metal (compd.) fine particles have 0.01 to 0.5 μm primary particle size. The primary particles of the composite particles preferably substantially have a flake-like form. Each flake-like particle has 0.001 to 1 μm thickness and at least 5 ratio (aspect ratio) of the max. length of the flake to the thickness. The composite particles are obtd. by using a silica sol as the starting material obtd. by dealkalization of an alkali silicate soln., dispersing the metal (compd.) fine particles in the sol, and subjecting the silica sol to hydrothermal treatment.
A nutrition tracking system comprises a nutrition tracking server, a plurality of weight-based food offering terminals, and one or more nutrition and meal information inquiry terminals. Multiple weight-based food offering terminals may be equipped on a food service cart. Each weight-based food offering terminal may be initialized to offer a type of food. The weight-based food offering terminal automatically measures the weight of food taken by a customer or for a customer, calculates the cost of food, and shows the weight and the cost on the display in real time. When the food is paid, the weight-based food offering terminal automatically reports the vending information to the nutrition tracking server. The nutrition tracking server maintains a database for customer meal information and a database for customer nutrition information. Customers may inquire their meal history and nutrition information using the nutrition and meal information inquiry terminals.
FIELD: medicine. ^ SUBSTANCE: method of determining prognosis of disease development in patient with cancer includes estimation of level of choline kinase alpha gene expression in cancer tissue sample, taken from patient, and comparison of obtained value with value, corresponding to one or more samples of normal non-cancer tissue. Higher level of choline kinase alpha gene expression is used to differentiate patients with worse prognosis of disease development. Method of in vitro monitoring of anti-cancer therapy effect is realised by estimation of level of choline kinase alpha gene expression in cancer tissue sample, taken from patient, who is introduced anti-tumour agent, and comparison of obtained value with value, corresponding to one or more samples of normal non-cancer tissue. Efficient therapy reduces levels of choline kinase alpha gene expression or causes reversing the effects of high expression of said gene. ^ EFFECT: invention makes it possible to determine prognosis of disease development in patient with cancer or carry out monitoring of anti-cancer therapy in patient in efficient way. ^ 6 cl, 47 dwg, 3 tbl, 11 ex
Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
Gastroesophageal Reflux illness is a multifactor pathology with a common mechanism: a prolonged exposure of the esophageal mucosa to the gastric solutions. Modification of the life style and the hygiene-dietetic habits are frequently recommended as an initial therapeutic instrument in Gastroesophageal Reflux pathology. But there is not agreement about the effectiveness of these habits in the improvement of the illness. Different clinical practice guidances have shown contradictions in the effectiveness of changing hygiene-dietetics habits of the life style. The high effectiveness of the new pharmacologic treatment in Gastroesophageal Reflux pathology make it necessary to review the role of hygiene-dietetic habits in this illness. Proton pump inhibitors (PPI) act in the final step of the gastric secretion. PPI's block ATP-ase H+/K+ in gastric parietals cells. This mechanism generates a higher acid inhibition, longer than the inhibition produced by H2-receptor antagonists. It has been described that inhibition of acid secretion has produced a recovery of the gastroesophageal pathology in a high percentage of the patients resistant to conventional drugs. This is an observational, multicenter, open and prospective study. The primary objective is to evaluate hygiene-dietetic habits as co-adjuvant of Rabeprazol treatment in Gastroesophageal Reflux . It is expected to include 570 patients with Gastroesophageal pathology erosive or non-erosive and acute or chronic treated with Rabeprazol per clinical practice, 20mg per day, orally, for 8 weeks. All data collected will be prospective and will include the following: demographic data, progress of the pathology, change of hygiene-dietetic habits, treatment adherence, concomitant treatments and adverse events. Observational Study - No investigational drug administered
PROBLEM TO BE SOLVED: To provide an outer container for an external preparation, allowing appropriately adjusting an application amount of a content in a tube container, and not being affected by a body temperature.SOLUTION: An outer container 1 for an external preparation includes a body part 3 incorporating a tube container 61, and a nozzle part 5 and a lid part mounted on the tube container 61. The body part 3 comprises a pair of half-split bodies 9a, and includes an opening 19, a support part, a pressing force part 23 and a bottom 25. The pressing force part 23 is formed so that an opposed surface to the tube container 61 nearly follows a trunk 67 from the bottom 25 to the opening 19. The pressing force part 23 is thicker in a bottom 25 side end than an opening 19 side end. With this, it is possible to appropriately contact the surface of the trunk 67 and prevent a content from remaining by squeezing the content from the end of the tube container 61. The outer container 1 for an external preparation covers the tube container 61 so as not to expose the tube container 61 to the outside, not to cause expansion of air by a body temperature due to not requiring direct pressing, and to prevent the content from being unexpectedly discharged.SELECTED DRAWING: Figure 2
A surgical image acquisition system includes multiple illumination sources, each source emitting light at a specified wavelength, a light sensor to receive light reflected from a tissue sample illuminated by each of the illumination sources, and a computing system. The computer system may receive data from the light sensor when the tissue sample is illuminated by the illumination sources, determine a depth of a structure within the tissue sample, and calculate visualization data regarding the structure and its depth within the tissue. The visualization data may have a format for use by a display system. The structure may include vascular tissue. The illumination sources may include red, green, blue, infrared, ultraviolet, and white light sources. The structure depth may be determined by a spectroscopy method or a Doppler shift method. The system may include a controller and computer enabled instructions to accomplish the above.
Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine \<20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission.
Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments. Trough levels provide information about clinically effective serum level range and confirm patient compliance, and are obtained just prior to the patient's next scheduled dose. Peak levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. Therapeutic effect without clinical signs of toxicity occurs more often with serum total concentrations between 10 and 20 mcg/mL (unbound phenytoin concentrations of 1 to 2 mcg/mL), although some mild cases of tonic-clonic (grand mal) epilepsy may be controlled with lower serum levels of phenytoin. In patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of unbound phenytoin concentrations may be more relevant [see Dosage and Administration (2.6)] . 

With recommended dosage, a period of seven to ten days may be required to achieve steady-state blood levels with phenytoin and changes in dosage (increase or decrease) should not be carried out at intervals shorter than seven to ten days.
Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD.
RECENT FINDINGS: Novel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical studies. In addition to traditional CVD risk factors, patients with CKD often present with non-traditional risk factors that include, e.g., anemia, proteinuria, or calcium-phosphate imbalance. Dyslipidemia remains an important contributing CVD risk factor in CKD, although the mechanisms involved differ from the general population. While statins are the most commonly used lipid-lowering therapy in CKD patients, some statins may require dose reduction. Importantly, statins showed diminished beneficial effect on cardiovascular events in patients with severe CKD and hypercholesterolemia despite high CVD risk and effective reduction of LDL cholesterol. Ezetimibe enables the reduction of the dose of statins and their putative toxicity and, in combination with statins, reduces CVD endpoints in CKD patients. The use of novel drugs such as PCSK9 inhibitors is safe in CKD, but their potential to reduce cardiovascular events in CKD needs to be elucidated in future studies.
The invention discloses centipede algae oligose and a preparation method and application thereof. The centipede algae oligose has a chemical structure shown in the specification. The preparation method comprises the following steps: firstly, carrying out acidic hydrolysis on centipede alga, and then separating and purifying. The experiment proves that the centipede algae oligose G19 provided by the invention can inhibit growth of tumor cells in vitro and in vivo, but does not affect growth of normal hepatocyte. The research shows that the inhibiting effect of the centipede algae oligose G19 relates to tumor cell cycle arrest and tumor cell apoptosis. Therefore, the centipede algae oligose G19 provided by the invention has a potential value of being developed into an anti-tumor drug which is low in toxicity and high in efficiency.
PROBLEM TO BE SOLVED: To obtain an extremely low-toxic anti-alopecic agent capable of markedly suppressing the aggravation of alopecia, esp. alopecia involving the use of anticancer agents, containing, as active ingredient, specific soybean protein- derived peptide(s). SOLUTION: This anti-alopecic agent contains, as active ingredient, 1-100 (pref. 10-100)wt.% of at least one kind of soybean protein-derived peptide of formula I to V, etc. The peptide(s) is obtained by enzymatic hydrolysis of soybean protein followed by fractionation of the resultant digest through DEAE- cellulose column chromatography followed by high-performance liquid chromatography using octadodecyl column and phenethyl column. This anti- alopecic agent can be administered orally or parenterally.
Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
Instability Resistance Training only group. Participants will receive 2 sessions per week over 6 weeks.